Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 14


CHICAGO — A drug derived from traditional Chinese medicine as an adjunct to guideline-directed therapy improved CV outcomes at 30 days and 1 year compared with placebo after revascularization, with no excess bleeding risk, a speaker reported.“Despite reperfusion and optimal medical therapy, patients with STEMI still face a high risk of in-hospital mortality, myocardial no-flow and